Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them
Athithi Verma August 20, 2026
Five mitochondrial drug classes named for CAR-T neurotoxicity, and the authors say none is under formal investigation. Every one is generic or preclinical.
Everyone's New Pharma Lane Runs Through Heathrow
Everyone’s New Pharma Lane Runs Through Heathrow
MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One
MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
Four Health Systems Automated the Prior Authorization Question, Not the Answer
Four Health Systems Automated the Prior Authorization Question, Not the Answer

Editor’s Pick

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

NeuroPulse


NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

OrphanPulse


OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

DealPulse Signal


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them

A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them

Athithi Verma August 20, 2026
Everyone's New Pharma Lane Runs Through Heathrow

Everyone’s New Pharma Lane Runs Through Heathrow

Athithi Verma August 20, 2026
MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One

MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One

Athithi Verma August 20, 2026
PDUFA VIII Keeps Every Review Clock and Hires Four Auditors

PDUFA VIII Keeps Every Review Clock and Hires Four Auditors

Athithi Verma August 20, 2026
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers

The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers

Athithi Verma August 20, 2026
Four Health Systems Automated the Prior Authorization Question, Not the Answer

Four Health Systems Automated the Prior Authorization Question, Not the Answer

Athithi Verma August 19, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress